AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
48.24
-2.02 (-4.02%)
Oct 1, 2026, 3:07 PM EDT - Market open
AnaptysBio Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 133.83 | 138.2 | 23.08 | 35.97 | 71.31 |
Short-Term Investments | 30.32 | 73.44 | 262.29 | 354.94 | 369.93 |
Cash & Short-Term Investments | 164.14 | 211.64 | 285.37 | 390.9 | 441.24 |
Cash Growth | -22.44% | -25.84% | -27.00% | -11.41% | -19.50% |
Accounts Receivable | 25.63 | 33.85 | 40.77 | 6.85 | 1.42 |
Other Receivables | 6 | - | - | - | - |
Receivables | 31.63 | 33.85 | 40.77 | 6.85 | 1.42 |
Prepaid Expenses | 2.65 | - | 1.18 | 9.08 | 4.55 |
Other Current Assets | - | 104.76 | 104.56 | - | - |
Total Current Assets | 198.43 | 350.25 | 431.88 | 406.84 | 447.21 |
Property, Plant & Equipment | 11.66 | 12.63 | 14.51 | 18.27 | 19.99 |
Long-Term Investments | - | - | 35.47 | 27.03 | 142.94 |
Long-Term Deferred Tax Assets | 106.64 | - | - | - | - |
Other Long-Term Assets | 0.26 | 1.52 | 1.97 | 0.26 | 0.26 |
Total Assets | 316.98 | 364.4 | 483.83 | 452.39 | 610.38 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 4.39 | 3.87 | 4 | 4.7 | 2.78 |
Accrued Expenses | 28.8 | 32.29 | 39.5 | 30.51 | 21.63 |
Current Portion of Leases | 2.16 | 2.08 | 1.93 | 1.78 | 1.64 |
Other Current Liabilities | - | 0.38 | - | 0.46 | - |
Total Current Liabilities | 35.35 | 38.63 | 45.43 | 37.44 | 26.05 |
Long-Term Debt | 256.49 | 276.53 | 353.43 | 310.81 | 304.41 |
Long-Term Leases | 10.93 | 12.03 | 14.11 | 16.04 | 17.81 |
Other Long-Term Liabilities | 3.62 | - | - | - | - |
Total Liabilities | 306.4 | 327.19 | 412.97 | 364.29 | 348.28 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
Additional Paid-In Capital | 652.27 | 809.77 | 829.86 | 702.97 | 717.8 |
Retained Earnings | -641.56 | -772.56 | -759.33 | -614.1 | -450.48 |
Comprehensive Income & Other | -0.15 | -0.02 | 0.31 | -0.8 | -5.25 |
Total Common Equity | 10.59 | 37.21 | 70.87 | 88.1 | 262.1 |
Shareholders' Equity | 10.59 | 37.21 | 70.87 | 88.1 | 262.1 |
Total Liabilities & Equity | 316.98 | 364.4 | 483.83 | 452.39 | 610.38 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 269.59 | 290.64 | 369.46 | 328.62 | 323.86 |
Net Cash (Debt) | -105.45 | -79 | -84.09 | 62.28 | 117.38 |
Net Cash Growth | - | - | - | -46.94% | -57.48% |
Net Cash Per Share | -2.81 | -2.61 | -2.85 | 2.31 | 4.17 |
Filing Date Shares Outstanding | 29.9 | 28.75 | 30.67 | 26.76 | 27.93 |
Total Common Shares Outstanding | 29.73 | 28.02 | 30.47 | 26.6 | 28.51 |
Working Capital | 163.07 | 311.63 | 386.45 | 369.39 | 421.15 |
Book Value Per Share | 0.36 | 1.33 | 2.33 | 3.31 | 9.19 |
Tangible Book Value | 10.59 | 37.21 | 70.87 | 88.1 | 262.1 |
Tangible Book Value Per Share | 0.36 | 1.33 | 2.33 | 3.31 | 9.19 |
Machinery | - | - | - | 8.11 | 7.46 |
Leasehold Improvements | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |